We are pleased to announce the CIACCO-2024 (11th Annual symposium on Cytokines in Inflammation, Ageing, CanCer and Obesity) on June 6-7, 2024 at "The Gait" Conference Hall, Bishop's University, Sherbrooke, QC.
Objectives of the event
CIACCO Symposia is a not-for-profit organization established through the collective effort of immunologists, microbiologists and cancer biologists from Université de Sherbrooke, Université de Montreal, McGill University, Université Laval and University of Ottawa.
CIACCO symposia seeks to advance education and research in cytokine biology by hosting an annual symposium featuring the latest research on physiological functions, pathological roles, regulatory mechanisms, and therapeutic targeting of cytokine signaling pathways in health and disease.
The major topics of CIACCO symposium include but are not limited to
· Cytokines in Inflammation and Immunity
· Cytokines in Ageing and Senescence
· Cytokines in Cancer Initiation, Progression and Control
· Cytokines in Obesity and Metabolism
CIACCO symposium attracts about 120 graduate students and faculty members, and hosts invited talks by established researchers and new investigators. CIACCO provides an ideal platform for students and postdocs to present their research, get feedback and establish contacts within the cytokine research community encompassing diverse fields of biomedical research in a convivial environment.
Taha Azad, PhD
Université de Sherbrooke
Laurent Sabbagh, PhD
Domain Therapeutics NA, Inc.
Laurent Sabbagh holds a Ph.D. in immunology from McGill University. Following his doctoral degree Dr. Sabbagh undertook post-doctoral fellowships at the Ontario Cancer Institute and the University of Toronto before being recruited by University of Montreal as an assistant professor working on the role of TNF receptors in immunological memory, inflammation and hematological malignancies. In the fall of 2013, Dr. Sabbagh was recruited by Vertex Pharmaceuticals (Canada) where he led biomarker discovery efforts for inflammatory bowel disease and small molecules drug discovery programs for polycystic kidney disease. Subsequently, Dr. Sabbagh led research programs aimed at drug discovery of small molecules for the treatment of inflammatory disorders and cancer at Paraza Pharma Inc. in Montreal. Laurent is currently Scientific Director at Domain Therapeutics (North America) leading drug discovery efforts of new molecules and antibodies targeting G protein-coupled receptors (GPCRs) in immuno-oncology and metabolic disorders.
Chandrakant Tayade, DVM PhD
Queen’s University, Kingston
Dr. Tayade earned a Doctor of Veterinary Medicine, master’s, and PhD in Immunology from the Indian Veterinary Research Institute. He then came to Canada to complete a postdoctoral fellowship at the University of Guelph. He joined Queen’s University in 2009 as an Assistant Professor and is currently working as a Professor, Vice-Dean of Basic and Public Health Sciences, and is the Director of MD PhD Program in the Faculty of Health Sciences. The central theme of Dr. Tayade’s research is focused on how immune dysfunction contributes to endometriosis pathophysiology and identifying immune based markers for diagnostic and therapeutic interventions. Dr. Tayade has published 105 peer-reviewed articles in journals such as JCI Insight, Journal of Immunology, American Journal of Pathology, American Journal of Obstetrics and Gynecology, and Trends in Molecular Medicine. He has received competitive funding from Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council of Canada (NSERC), Endometriosis Foundation of America and Bayer. For his outstanding contributions to research, Dr. Tayade has received a number of special recognitions. In 2012, he won both the Early Researcher Award from the Ministry of Research and Innovation as well as the Christian J Herr Award for Outstanding Contributions in Reproductive Immunology from the American Society for Reproductive Immunology. In 2014, he earned the Mihran and Mary Basmajian Award for Research Excellence from the Queen’s Faculty of Health Sciences.
Cedric Tremblay, PhD
University of Manitoba
Susan E. Waltz, PhD
University of Cincinnatti, USA
Dmitriy Zamarin, MD PhD
Icahn School of Medicine, NY
Dmitriy Zamarin MD PhD is the Section Head of Gynecologic Medical Oncology and is a member of the Icahn Genomics Institute and the Precision Immunology Institute at the Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai. He is a medical oncologist specializing in the care of women with gynecologic cancers, including cervical, ovarian, and endometrial cancers.
Dr. Zamarin obtained his MD and PhD degrees from the Mount Sinai School of Medicine. He completed residency in Internal Medicine at the Mount Sinai Hospital and fellowship in Hematology/Oncology at the Memorial Sloan Kettering Cancer Center, where his research was focused on the mechanisms of response and resistance to cancer immunotherapy and development of novel immunotherapy treatment approaches. He has spent a decade as a faculty and Translational Research Director in Gynecologic Medical Oncology at the Memorial Sloan Kettering Cancer Center before transitioning to his current role in September of 2023.
Dr. Zamarin has served as a principal investigator and a translational chair on multiple institutional and cooperative group clinical trials exploring novel immunotherapy combinations in gynecologic cancers and other solid tumors and serves as the translational research co-chair on the NRG Oncology Cervical Cancer committee. In the laboratory, his research is focused on understanding of the mechanisms by which gynecologic cancers are recognized by the immune system and on identification of biomarkers predictive of response and resistance to immunotherapy. His laboratory uses mouse models to explore the mechanisms of tumor-immune system interactions and to develop novel therapeutics, with particular focus on oncolytic viruses, vaccines, and targeted therapies. For his work Dr. Zamarin has received awards and funding from multiple organizations including Damon Runyon Foundation, Ovarian Cancer Research Alliance, Department of Defense, and R01 grants from the National Cancer Institute.
Akouavi Julite Irmine Quenum (PhD - Microbiology & Infectious diseases)
Laiyen Garcia Delgado (PhD - Pharmacology & Physiology)
Noah Wirasinghe (MSc - Experimental Medicine)
Sara Ali Akbari (PhD - Immunology & Cell Biology)
Fjolla Rexhepi (PhD - Immunology & Cell Biology)
Moutih Rafei, PhD. Department of Pharmacology (U de Montréal)
Caroline Saucier, PhD, Department of Immunology and Cell Biology (U de Sherbrooke)
Gerardo Ferbeyre, MD, PhD. Department of Biochemistry (U de Montréal)
Sonia Del Rincon, PhD. Lady Davis Institute (McGill University)
Seung-Hwan Lee, PhD. Department of Biochemistry, Microbiology and Immunology (U Ottawa)
Manu Rangachari, PhD. Department of Molecular Medicine (U Laval)
Sheela Ramanathan, PhD. Department of Immunology and Cell Biology (U de Sherbrooke)
Alfredo Menendez, PhD, Dept of Microbiology and Infectious diseases (U de Sherbrooke)
Jörg Fritz, PhD. Dept of Microbiology and Immunology (McGill University)
Subburaj Ilangumaran, PhD. Department of Immunology and Cell Biology (U de Sherbrooke)
Please contact email@example.com for Sponsorship details
Bishop's University2600, Rue College Sherbrooke, QC Canada, J1M 0C8
January 22, 2024 - 08:00 until May 3, 2024 - 23:59
January 22, 2024 - 08:00 until May 3, 2024 - 23:59
If you have any questions, please contact firstname.lastname@example.org .